Advisory board
Leah Klapper PhD, Chief Technology Officer, FutuRx Biotech Accelerator
Dr. Leah Klapper has been in R&D leadership positions in biotech start-ups for close to 20 years, advancing innovation from discovery to clinical proof of concept. Before joining FutuRx, she served as CSO at Regenovation and BioLineRx Ltd., and as VP R&D at CureTech Ltd. Dr. Klapper holds a PhD from the Weizmann Institute of Science. She did her post-doctoral training at the Fred Hutchinson Cancer Research Center in Seattle, Washington.
Erez Podoly, PhD, VP of R&D at Cleveland Diagnostics
Dr. Erez Podoly is the VP of R&D at Cleveland Diagnostics, leading the development of next-generation, high sensitivity and specificity diagnostic products. Previously, he headed Therapeutic and Diagnostic Investments at Cleveland Clinic Ventures, launching and funding startups, and serving on their boards. Erez also founded and led VC-backed biosensing startups and worked at Artiman Ventures on early-stage investments. Dr. Podoly holds a BSc in Chemistry, an MSc in Biochemistry, and a PhD in Neurobiology and Structural Biology. He conducted postdoctoral research at Stanford with Nobel Laureate Dr. Roger Kornberg. An award-winning scientist, Erez co-authored numerous papers in leading journals.
Ofer Ashulin,
B.Sc. and VMD graduate from the Hebrew University. MBA from Haifa University.
Over 30 years of diverse clinical experience across multiple animal species.
Specialized expertise in equine medicine and aquaculture.
Tal Peleg-Shulman, LL.B., Adv., Ph.D. Medicinal Chemistry
Angel investor and R&D executive with deep expertise in due diligence and venture building, Tal advises and mentors early-stage startups. As Director of Chemistry, Manufacture & Control at Ncurim Pharmaceuticals, she was instrumental in launching CircadinTM globally.